Journal of Global Infectious DiseasesOfficial Publishing of INDUSEM and OPUS 12 Foundation, Inc. Users online:636  
Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size     
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 

UPDATE ARTICLE Table of Contents   
Year : 2010  |  Volume : 2  |  Issue : 3  |  Page : 248-257
Human immunodeficiency virus and leishmaniasis

1 Department of Medicine, Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, USA
2 Department of Medicine, Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles; Department of Medicine, Divisions of Dermatology and Infectious Diseases, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA, USA

Click here for correspondence address and email

Date of Web Publication17-Aug-2010


The leishmaniases are a group of diseases transmitted to humans by the bite of a sandfly, caused by protozoan parasites of the genus Leishmania. Various Leishmania species infect humans, producing a spectrum of clinical manifestations. It is estimated that 350 million people are at risk, with a global yearly incidence of 1-1.5 million for cutaneous and 500,000 for visceral leishmaniasis (VL). VL is a major cause of morbidity and mortality in East Africa, Brazil and the Indian subcontinent. Co-infection with human immunodeficiency virus (HIV) alters the immune response to the disease. Here we review the immune response to Leishmania in the setting of HIV co-infection. Improved understanding of the immunology involved in co-infections may help in designing prophylactic and therapeutic strategies against leishmaniasis.

Keywords: AIDS, Co-infection, HIV, Immunology, Leishmaniasis

How to cite this article:
Ezra N, Ochoa MT, Craft N. Human immunodeficiency virus and leishmaniasis. J Global Infect Dis 2010;2:248-57

How to cite this URL:
Ezra N, Ochoa MT, Craft N. Human immunodeficiency virus and leishmaniasis. J Global Infect Dis [serial online] 2010 [cited 2023 Feb 1];2:248-57. Available from:

   Introduction Top

The protozoan parasite Leishmania is highly prevalent in many areas of the world. Moreover, leishmaniasis is now gaining higher clinical importance in individuals infected with HIV-1 (human immunodeficiency virus type 1) because the distribution of both infectious agents overlaps in numerous parts of the world (e.g., Mediterranean basin, South America, India and many African countries). There is no doubt that the actual number of documented cases of co-infection is underestimated due to the various problems in recognition, diagnosis and reporting of either HIV-1 infection, or leishmaniasis or both, in the setting of developing countries. The fact that leishmaniasis is not included among the acquired immune deficiency syndrome (AIDS)-defining diseases contributes to this scarcity of information.

Leishmaniasis is transmitted to humans by the bite of a sandfly, and disease progression can be influenced by host immunity. Upon entering the host, the primary target cells are macrophages of the skin or viscera depending on the species of Leishmania. Immunologic control of Leishmania infection depends on both the innate and adaptive immune systems. About 1.5 million new cases of leishmaniasis are documented each year, and over 350 million people live in areas of active parasite transmission. [1] Co-infection of Leishmania and HIV has been reported frequently, yet the immunological relevance of co-infection is not well documented. Both infections affect human populations across southern Europe, Africa, the Middle East, Central and South America, Southeast Asia, and the Indian subcontinent. In this article, we compare the immunology of leishmaniasis with that of HIV and discuss the potential clinical importance of co-infection.

   HIV Immunology Top

AIDS occurs in individuals whose immune system fails due to an overload of human immunodeficiency virus (HIV) and a decreased CD4+ T cell population [Figure 1]. Opportunistic infections not commonly observed in the healthy population, such as tuberculosis, fungal infections and pneumocystis carinii pneumonia, are common in AIDS patients.
Figure 1 :The immunology of resolving infection and disease progression to Leishmania For both T helper 1 (TH1)- and TH2-cell differentiations, antigens are presented to naive CD4+ T cells by dendritic cells (DCs). The interaction of co-stimulatory molecules with their respective ligands, together with the local cytokine environment, promotes the differentiation of naive T cells into interferon- γ (IFN-γ)-secreting TH1 cells or interleukin-4 (IL-4)-secreting TH2 cells. In TH1-cell development, certain pathogens or pathogen-associated molecular patterns (PAMPs) trigger antigen-presenting cells, through toll-like receptors (TLRs), to secrete IL-12, which promotes the differentiation of naive T cells into IFN-γ-secreting TH1 cells. In TH2-cell development, the inability of antigen to activate DCs to produce IL-12 results in a default pathway of naive T-cell differentiation into IL-4-secreting TH2 cells

Click here to view

Since AIDS was first described over 25 years ago, [2],[3] scientific advances have significantly expanded our understanding of the immune system. Following the initial burst of viremia during primary infection, HIV-infected individuals mount a robust immune response that usually curtails the levels of plasma viremia, delaying the development of clinically apparent disease for a median of 10 years. This immune response contains elements of both humoral and cell-mediated immunity directed against multiple antigenic determinants of the HIV virus, as well as against viral proteins expressed on the surface of infected cells.

CD4+ T cell subsets, designated T helper (T H 1) that produce interferon gamma (IFN-γ), interleukin (IL)-2, IL-12, IL-15 and IL-18 are responsible for protective effects against pathogens mediated primarily through cellular immunity, whereas Th2 subsets that produce IL-4, IL-5 and IL-10 result in protective effects against pathogens mediated primarily through humoral mechanisms. [4]

Numerous immune-modulating approaches have been studied in both animal models of HIV and human vaccination. [5],[6],[7] IFN-γ, IL-2, IL-12, IL-15 and IL-21 have all been employed in multiple studies of DNA vaccines targeted against HIV or simian immunodeficiency virus (SIV). [8],[9],[10],[11],[12],[13] These adjuvants help establish a strong CD8+ T cell response against antigens delivered via DNA vaccination. IL-2 and IL-12 in particular create robust anti-HIV cytotoxic T lymphocyte (CTL) responses. [9],[10] IL-12, both on its own and in conjunction with IL-15, induces potent type-1 responses in rhesus macaques that have led to greatly improved clinical outcomes and control of viremia. [10],[11] These studies suggest that the use of IL-12 and IL-15 in DNA vaccination against HIV or SIV leads to improved generation of CTL responses.

It has been suggested that IL-15 can prime CTLs to better degranulate in response to T-cell antigen receptor (TCR) ligation, [14] and IFN-γ may have positive results in inducing CTL activity in mouse models. [15] However, adjuvants that are effective in mouse models may not necessarily show the same potency in primates. [16]

The macrophage plays a principal role in the life cycle of HIV-1 infection. [17] A delta32 mutation in the major co-receptor for macrophage tropic HIV-1 infection, CCR5, plays a protective role, which suggests the macrophage may be the initial cell type infected by HIV-1 in vivo.[18] Rhesus macaques infected with simian-human immunodeficiency virus 1 SHIV-1 chimera displayed macrophage reservoirs with high viral loads of SHIV-1 even after CD4+ T cell depletion. [19] Macrophages in HIV-1-infected patients on highly active antiretroviral therapy (HAART) harbor the virus during antiretroviral therapy and release HIV-1 upon withholding drug therapy. [20],[21] HIV-1-infected tissue macrophages tend to be long-lived cells that increase in number during the course of HIV-1 infection and provide a location for the expanding viral load, even during the terminal stages of HIV-1 infection, when the CD4+ T cell compartment is decimated. [17]

Host immune response to Leishmania

The immune response to Leishmania infection is cell mediated, and clinical symptoms depend on whether the host mounts a Th1 or Th2 response. [22],[23] The same parasite epitope can induce either a Th1 response with resolving infection or a Th2 response with disease progression. [24] Although the primary cell type infected is the macrophage as part of innate immunity, control of the disease hinges on the adaptive immune response.

Th1 and Th2 cells can cross-regulate each other, thereby suppressing/ enhancing each other's effects. [4] Lymphocytes from subjects who are able to limit their infection to the protozoan parasite Leishmania exhibit a predominant Th1 response upon stimulation with Leishmania antigens in vitro. [25],[26] Patients with active VL, in contrast, display an impaired Th1 response, [26],[27] whereas Th2 responses, in particular IL-10 production, have been reported to increase. [28],[29] This type of response to infection often results in disseminated disease and increased mortality.

Although much of the protection against
Leishmania is mediated by Th1 CD4+ cells, [30] Leishmania-reactive IFN-γ-producing CD8+ T cells have also been associated with cure of some forms of leishmaniasis. [31] In addition, mononuclear cells from healthy individuals with no previous exposure to Leishmania proliferate in response to Leishmania antigens in conjunction with high IFN-γ and IL-6 response. [32]

Natural killer (NK) cells and CD8+ T cells also play a role in effective clearance of cutaneous leishmaniasis (CL). [33] While all three cell types are capable of secreting IFN-γ, it is IL-12 and IL-18 that direct the differentiation and proliferation of uncommitted Th cells toward the Th1 subset and stimulate the release of IFN-γ by Th1 and NK cells. [34],[35]

Many cytokines play a role in the cell-mediated immunity toward leishmaniasis. IL-2, IL-3 and IFN-γ are produced by CD4+ T cells in the Th1 response to promastigotes attaching to reticuloendothelial cells. [36] IL-12 and tumor necrosis factor (TNF) play an important role in the activation of macrophages, [36] a component of innate immunity. Additionally, genetic influences on the type of immune response initiated toward the Leishmania species have revealed genes thought to have a major role in the outcome of infections such as those coding for natural resistance-associated macrophage protein 1 (NRAMP-1), TNF or the major histocompatibility complex. [36],[37] Additionally, macrophage activation via the SLC11A1 (formerly NRAMP1) gene, and polymorphisms in the gene encoding IL-4, are also associated with increased susceptibility to VL and post-kala-azar dermal leishmaniasis (PKDL) in Sudan. [38] This supports the notion of innate immunity being the key driving force toward the adaptive host immune response.

Thus, host-determined delayed-type hypersensitivity, antigen-specific T cell reactivity and cytokine secretion all combine with the specific strain and virulence of the infecting Leishmania species to determine the ultimate clinical presentation of the disease.

Innate immunity

The innate immune system comprises the cells and mechanisms that defend the host in a nonspecific manner from infection by other organisms. Although skin parasite infections are mainly controlled by adaptive, as opposed to innate, immune mechanisms, the skin innate immune system functions to detect invading parasites, recruit inflammatory cells to sites of invasion and facilitate and promote the induction of adaptive immunity. Systems such as toll-like receptors (TLRs) and complement receptors (CRs) help to detect the presence of infection and to induce activation of inflammatory and antimicrobial innate immune responses. Recognition of microbial products by TLRs expressed on dendritic cells (DCs) triggers functional maturation of DCs and leads to initiation of antigen-specific adaptive immune responses. [39] Innate immunity against Leishmania involves recognition receptors (TLRs), cell types (myeloid dendritic cells, plasmacytoid dendritic cells), cytokines (IL-12, IFN-α/β) and signaling pathways (Tyk2 kinase) that are necessary for the initial sensing of the parasites and the subsequent development of an efficient NK cell response.[40]

TLRs mediate activation by microbial ligands, including lipoproteins, resulting in the activation of IL-12 and nitric oxide synthase. [41] Microbial lipoproteins also induce host cell apoptosis. One of the antimicrobial products that can directly destroy pathogens, nitric oxide, is induced by TLR activation. [42] In this manner, the ability of microbial lipoproteins to activate TLRs can contribute to host defense and immunopathology during infection. More than ten TLRs have been identified in humans, [43] with keratinocytes expressing TLR1 and TLR4 and DC expressing TLR1, 2, 4 and 6. [44],[45]

Leishmania mexicana DNA contains nonmethylated CpG motifs capable of activating murine bone marrow-derived macrophages, leading to the production of pro-inflammatory cytokines such as TNF-α and IL-12, as well as the overexpression of mRNA for TLR9. [46] CpG motifs are considered pathogen-associated molecular patterns (PAMPs) due to their abundance in microbial genomes but their rarity in vertebrate genomes. The CpG PAMP is recognized by the pattern recognition receptor (PRR) Toll-Like Receptor 9 (TLR9), which is only constitutively expressed in B cells and plasmacytoid dendritic cells (pDCs) in humans and other higher primates. Although TLR9 deficiency leads to a transient increase of IL-4, IL-13 and arginase 1 mRNA and a reduced expression of iNOS at the site of infection and in the draining lymph nodes, it does not prevent the development of Th1 cells and the ultimate resolution of the infection. [47] Therefore, TLR9-signaling is essential for NK cell activation but dispensable for a protective T cell response to L. major in vivo.[47] The common downstream pathways of TLR lead to the induction of various genes involved in host defense, including inflammatory cytokines, chemokines, major histocompatibility complex MHC and co-stimulatory molecules. [48]

Different patterns of chemokine expression in TLR-competent and -deficient mice after infection with L. major were detected depending on the post-infection time and irrespective of TLR4. [49] Genetically resistant mice lacking MyD88-adapter protein, the common downstream adaptor protein responsible for TLR and IL-1 signaling, display a high susceptibility to L. major infection associated with a polarized Th2 response. [50] Although the exact mechanism of action for this effect in L. major infections is not known, the majority of genetically deficient mice are thought to have the phenotype due to defects in TLR-signaling. [51]

Both the classical and the alternative pathways of the complement system are activated in Leishmania infections once promastigotes penetrate the dermis and react with serum. [52] Lysis via the membrane attack complex (C5b-C9 complex) begins 60 seconds after serum contact, [52] resulting in efficient killing of more than 90% of all inoculated parasites within a few minutes. Hence there is only a slight chance for parasite survival and establishment of an infection since most inoculations of Leishmania parasites are aborted early on due to complement killing. [48]

One TNF superfamily member, LIGHT, is known to enhance inflammation and T cell-mediated immunity and is important for optimal IL-12 production by DC and for the development of IFN-γ-producing CD4+ Th1 cells. [53] LIGHT is an acronym that stands for: is homologous to Lymphotoxins, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes. LIGHT has also been called HVEM-L and LT-gamma. Its blockade results in increased susceptibility to L. major.[53]

Data from multiple studies point to NK cell effector function in leishmaniasis as being cytokine mediated rather than cytotoxicity mediated. [54],[55],[56],[57],[58] IL-12 and IL-18 are major regulators of innate and adaptive immune responses to L. major infection. [59],[60] L. major- and L. donovani-susceptible mice are effectively cured by treatment with exogenous IL-12, [61],[62] and the lack of NK cell-activating chemokines results in suboptimal NK cell-mediated defense. [63]

Rapid IFN-γ production during the first hours and days of L. major infection is crucial for survival, and NK cells are the initial source of this cytokine. [33],[56],[59] Furthermore, severe combined immunodeficient (SCID) mice, which lack T cells but have normal NK function, are able to contain L. major parasites in the draining lymph nodes, arguing for the existence of a T cell-independent mechanism to limit parasite spread. Neutralization of IFN-γ or depletion of NK cells prior to infection of SCID mice retards their ability to control parasite spread. [64]

Multiple studies suggest dendritic cells provide the principal source of IL-12 early in leishmaniasis, triggering NK cell activation. [65],[66] Direct stimulation of the TLR-2 on NK cells by an L. major lipophosphoglycan (LPG) leads to up-regulation of TLR-2 and increased production of IFN-γ and TNF-α,[67] suggesting the existence of an additional, accessory cell-independent route of NK cell activation in leishmaniasis. It has been suggested that accessory cell-derived cytokines may be required for amplification of the direct response. [68]

Adaptive immune response

Previous animal studies suggest that different strains of leishmaniasis induce different host immune responses, and that a Th1 response results in resolution of infection whereas a Th2 response results in development of severe disease. [22] The Th1 response produces INF-g, which correlates with resistance; whereas the Th2 response produces IL-4 and correlates to susceptibility to infection. [69] In humans, IL-4, a component of the Th2 response, is also associated with disease development. [70],[71]

It is well known that CD8+ T cells are essential in the defense against viruses, yet little is known of their participation in the host defense against parasites. Murine models of leishmaniasis suggest that CD8+ T cells participate through IFN-γ production. [72] There is also a large cytotoxic factor that plays an important role in cytotoxicity and apoptosis of autologous Leishmania-infected macrophages leading to cure. [72] It has been postulated that dendritic cells activate CD8+ T cells through mechanisms that include antigen cross-presentation, yet the exact mechanisms underlying CD8+ T cell activation in patients with leishmaniasis are unknown. [72]

The host-specific cell-mediated immunity (CMI) is important in Leishmania control, demonstrated by the unresponsiveness to L. donovani antigens [26] and the production of IL-10 [29] in L. donovani-infected VL patients. Elevated levels of IL-10 in VL patient plasma significantly enhance the growth of L. donovani amastigotes in human macrophages, and IL-10-producing CD25(-)Foxp3(-) T cells may be important in the pathogenesis of human VL. [73]


Our understanding of the epidemiological, biological and clinical interactions between HIV and tropical pathogens has lagged compared with our understanding of the interactions between HIV and pathogens that are common in the industrialized world. [74]

Cases of HIV and VL co-infection have been reported in 35 countries worldwide. [75] The highest prevalence of co-infection occurs mostly in Spain and southwestern Europe, with injectable drug users being at the highest risk of inoculating themselves intravenously with used syringes. [76]

The presence of both pathogens concomitantly in the same host cell (the macrophage) has enhanced reciprocal effects that influence the expression and multiplication of either one or both pathogens. [77] A vicious circle is established whereby the protozoan parasite Leishmania induces a more robust HIV-1 production and the virus mediates a greater parasitic replication. Indeed, it has been shown that HIV-1 infection increases the risk of developing VL by 100 to 2,300 times in areas of endemicity, reduces the likelihood of a therapeutic response and greatly increases the probability of relapse. Moreover, clinical studies have revealed that leishmaniasis promotes an increase in viral load and a more rapid progression to AIDS, which reduces life expectancy in HIV-1-infected patients. Thus, both pathogens exert a synergistic detrimental effect on the cellular immune response because they can establish infection in similar host immune cells.

Due to the depletion of both the cellular and humoral responses to Leishmania in co-infected patients, [78] there is an increased risk of disease progression of leishmaniasis after Leishmania infection in HIV+ individuals. In individuals with nonfunctional T-lymphocytes, such as in HIV-infected patients, Leishmania infection becomes increasingly problematic. [77]

It is thought that the parasite infection found concurrently with HIV induces chronic immune activation, and therefore an increased HIV load and accelerated progression towards AIDS. [77],[80],[81] In addition, immunological disturbances caused by HIV are particularly favorable for the uncontrolled multiplication of the parasite.

L. infantum amastigotes have been recently shown to enhance HIV-1 production in co-cultures of human dendritic cells and CD4 T cells by inducing secretion of IL-6 and TNF-α. [82] L. donovani can also up-regulate HIV-1 replication, both in monocytoid and lymphoid cells in vitro and in co-infected individuals. Not all species of Leishmania have been found in HIV-1-infected individuals. For example, in co-infected patients, VL is caused primarily by L. infantum and L. donovani. Other species of Leishmania, such as L. ethiopica, L. braziliensis, L. major and L. tropica, have been described as being responsible for cases of co-infection, according to the geographical area concerned. Leishmania can act as a powerful co-factor in the pathogenesis of HIV-1 infection. In those who are co-infected, complex mechanisms involving cytokine secretion and cellular-signaling events play pivotal roles in the Leishmania-mediated activation and pathogenesis of HIV-1. [83]

HIV infects CD4+ helper T cells, macrophages and dendritic cells. Upon infection, the virus uses the cell as a host in order to replicate. The host immune cell is eventually destroyed, leading to higher susceptibility of the organism to disease. In the Th1 response to leishmaniasis, promastigotes attach to reticuloendothelial cells, causing CD4+ cells to produce IL-2, IL-3 and IFN-γ. These molecules activate macrophages that phagocytose the promastigotes, leading to active leishmaniasis. Leishmaniasis and HIV create a synergy for destruction of cell-mediated immunity and susceptibility toward opportunistic pathogens.

HIV-1 can suppress Leishmania-induced cellular proliferation in vitro.[77] Furthermore, HIV does not affect the synthesis of cytokines TNF-γ and IL-6 induced by lipopolysaccharide or parasites. [77],[84],[85] Although the exact mechanism by which HIV may induce reduced cellular responses to Leishmania is unknown, the observed inhibitory effects of HIV on Leishmania-induced responses may have to do with decreased inductive signals for IFN-γ and/ or a decrease in cytokines of the Th2 type on Leishmania-reactive Th1 cells. [77]

Resolution of leishmaniasis infection depends on T-cell-dependent immunity and requires an intact CD4+ cell-mediated response of the Th1-cell-associated phenotype. This complex response is regulated by multiple inflammatory cytokines, including IL-2, IL-12, IL-15, IL-18, in addition to IFN-γ and TNF-α. The stimulation induces a potent intracellular leishmanicidal mechanism in phagocytes to kill residual surviving parasites. [86]

In most individuals that develop a clinically significant leishmaniasis infection, the Th1 cell response fails to fully develop. The Th2-associated CD4+ T cell response is triggered alongside IL-4, IL-5 and IL-10. It has been postulated that the antigen-specific immunosuppression observed in disseminated CL and the resulting clinical syndrome could partially be due to the ability of the infecting parasite to induce a predominance of IL-10 over IFN-γ. [87] This Th2 mechanism inhibits macrophage activation, thereby permitting intracellular replication of the parasite. [85] HIV plays an important role in induction of a Th2-like state, along with CD4+ T cell depletion, ultimately inhibiting the Th1-type cytokine secretion and increasing susceptibility to infection. [85]

Co-infection of HIV and Leishmania produces cumulative deficiency of host CMI, a key factor for primary protection against infection, recurrences or spread of parasites. [89] An HIV-infected patient with CL may display an atypical and severe clinical presentation of CL in terms of number (>200), sites and types of lesions (papulonodular). [89] Uncommon sites of infection are more frequent, such as the gastrointestinal tract or the upper respiratory tract. [36] Diffuse CL was seen in south India masquerading as lepromatous leprosy in the context of HIV infection. [90] There are even reports of HIV patients presenting with malabsorption, with workup revealing VL with skin and small-bowel infiltration. [91]

Co-infected patients tend to have false-negative results with the direct agglutination test (DAT) used to test for Leishmania antibodies, [92],[93] an increased parasite load in blood and bone marrow, lower sensitivity of serological tests and a higher rate of treatment failure. [86],[94] Typical symptoms that must be kept in mind when evaluating an HIV+ patient for VL are apyrexia, pancytopenia and hepatosplenomegaly. However, splenomegaly may be absent in HIV. [23]

Mucosal lesions of CL in an HIV patient should not be considered as mucocutaneous leishmaniasis, since parasites commonly disseminate and involve nasal and oral mucosa. [95],[96] Diffuse CL in the absence of visceral involvement has been reported as a first manifestation leading to the diagnosis of HIV infection. [89]

In some developed countries in Europe and North America, VL is becoming a more common opportunistic infection in immunocompromised people. [86],[97] VL infection in an HIV+ individual is associated with a high post-treatment relapse rate of 52% between 1 month and 3 years. [98] VL in HIV infection has been proposed for inclusion in the Centers for Disease Control and Prevention clinical category C for the definition of AIDS as an indicator disease. [97]

A recent study investigated the effect of HIV aspartyl peptidase inhibitors (PIs) on the Leishmania amazonensis proliferation, ultrastructure, interaction with macrophage cells and expression of classic peptidases which are directly involved in Leishmania pathogenesis. [99] They found that HIV PIs impaired parasite growth in a dose-dependent fashion, especially nelfinavir and lopinavir. Profound changes in the Leishmania ultrastructure were displayed by transmission electron microscopy, including cytoplasm shrinking, increase in the number of lipid inclusions and some cells presenting the nucleus closely wrapped by endoplasmic reticulum resembling an autophagic process, as well as chromatin condensation which is suggestive of apoptotic death. [99] The in vitro insight into the synergistic effects of classical antileishmanial compounds and HIV PIs in macrophages co-infected with Leishmania and HIV-1 should prove to be promising research.

There is an increased risk of treatment failure in leishmaniasis patients co-infected with HIV, independent of the antileishmanial pharmacologic agent administered. [100],[101],[102] A wide variety of treatment modalities exist for the diverse spectrum of clinical disease. Generic pentavalent antimonials have been the mainstay for therapy in endemic regions due to efficacy and cost-effectiveness, yet the growing incidence of resistance towards these therapeutics has seriously hampered their use.

Many of the drugs employed for the treatment of leishmaniasis, such as pentamidine and amphotericin, are toxic, marginally effective, given by injection and compromised by emerging drug resistance. Although treatment of HIV and leishmaniasis co-infection has not been adequately studied, pentavalent antimonials continue to be used extensively. [103]

Miltefosine is the first effective oral drug against VL, yet there is limited data on its role against the increasing problem of HIV-associated VL. [104] Miltefosine alone has failed to cure relapsing VL in HIV-infected patients; [105] however, it can be attempted in co-infected individuals for whom standard leishmaniasis treatment has failed. [100] Treatment with miltefosine is equally effective as standard sodium stibogluconate treatment in non-HIV-infected men with VL. [106] Among HIV-co-infected patients, miltefosine is safer, but less effective, than sodium stibogluconate. [106] Recently, miltefosine and sodium stibogluconate, in combination, have been used successfully for the treatment of an HIV-positive patient with VL. [107]

In a randomized trial comparing meglumine antimonate with amphotericin B in the treatment of VL in HIV-infected patients, relapse rate did not appear to be affected by the type of treatment given. [102] Meglumine antimonate and liposomal amphotericin have only been compared in smaller studies, in which minimal differences were found. [108] Liposomal amphotericin B is preferable to meglumine antimonate because of reduction in hospital stay; patient convenience may balance the cost of medication. [109]

Some have used secondary prophylaxis with antileishmanials to prevent relapses, and, although effective, there is no standardized regimen. [95],[111] Highly active antiretroviral therapy (HAART) partially restores immune function but does not entirely prevent leishmaniasis relapses. [112],[113] In contrast, a sharp decrease in the incidence of VL in Europe was observed following the widespread use of HAART, [114],[115] further supporting the notion that HAART helps prevent VL in individuals infected by Leishmania.[116]

In summary, HIV and Leishmania both modulate host immunity in ways that may affect the detection, pathogenesis and prognosis of the other infection. Because of an increased prevalence of co-infection in an era of continuously expanding global HIV infection, clinicians and scientists should be aware of the immune interactions between these two diseases. Additionally, astute providers in non-endemic countries for leishmaniasis should be aware of the risk of co-infection and address this possibility appropriately.

   References Top

1.Cruz I, Nieto J, Moreno J, Canavate C, Desjeux P, Alvar J. Leishmania/HIV co-infections in the second decade. Indian J Med Res 2006;123:357-88.  Back to cited text no. 1      
2.Centers for Disease Control (CDC). Pneumocystis pneumonia-Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2.  Back to cited text no. 2      
3.Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981;305:1425-31.  Back to cited text no. 3      
4.Mosmann TR, Coffman RL. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.  Back to cited text no. 4      
5.Evans TG, McElrath MJ, Matthews T, Montefiori D, Weinhold K, Wolff M, et al. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 2001;19:2080-91.  Back to cited text no. 5      
6.O'Hagan DT, Ugozzoli M, Barackman J, Singh M, Kazzaz J, Higgins K, et al. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. Vaccine 2000;18:1793-801.  Back to cited text no. 6      
7.McBurney SP, Ross TM. Developing broadly reactive HIV-1/AIDS vaccines: A review of polyvalent and centralized HIV-1 vaccines. Curr Pharm Des 2007;13:1957-64.  Back to cited text no. 7      
8.Kim JJ, Nottingham LK, Tsai A, Lee DJ, Maguire HC, Oh J, et al. Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants. J Med Primatol 1999;28:214-23.  Back to cited text no. 8      
9.Barouch DH, Craiu A, Kuroda MJ, Schmitz JE, Zheng XX, Santra S, et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A 2000;97:4192-7.  Back to cited text no. 9      
10.Chong SY, Egan MA, Kutzler MA, Megati S, Masood A, Roopchard V, et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine 2007;25:4967-82.  Back to cited text no. 10      
11.Boyer JD, Robinson TM, Kutzler MA, Vansant G, Hokey DA, Kumar S, et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A 2007;104:18648-53.  Back to cited text no. 11      
12.Horiuchi R, Akahata W, Kuwata T, Enose Y, Ido E, Suzuki H, et al. DNA vaccination of macaques by a full-genome SHIV plasmid that has an IL-2 gene and produces non-infectious virus particles. Vaccine 2006;24:3677-85.  Back to cited text no. 12      
13.Bolesta E, Kowalczyk A, Wierzbicki A, Eppolito C, Kaneko Y, Takiguchi M, et al. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. J Immunol 2006;177:177-91.  Back to cited text no. 13      
14.White L, Krishnan S, Strbo N, Liu H, Kolber MA, Lichtenheld MG, et al. Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV). Blood 2007;109:3873-80.  Back to cited text no. 14      
15.Ihata A, Watabe S, Sasaki S, Shirai A, Fukushima J, Hamajima K, et al. Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1. Immunology 1999;98:436-42.  Back to cited text no. 15      
16.Morrow MP, Weiner DB. Cytokines as adjuvants for improving anti-HIV responses. AIDS 2008;22:333-8.  Back to cited text no. 16      
17.Haine V, Fischer-Smith T, Rappaport J. Macrophage colony-stimulating factor in the pathogenesis of HIV infection: Potential target for therapeutic intervention. J Neuroimmune Pharmacol 2006;1:32-40.  Back to cited text no. 17      
18.Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-5.  Back to cited text no. 18      
19.Igarashi T, Brown CR, Endo Y, Buckler-White A, Plishka R, Bischofberger N, et al. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A 2001;98:658-63.  Back to cited text no. 19      
20.Lambotte O, Taoufik Y, de Goer MG, Wallon C, Goujard C, Delfraissy JF. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;23:114-9.  Back to cited text no. 20      
21.Garbuglia AR, Zaccarelli M, Calcaterra S, Cappiello G, Marini R, Benedetto A. Dynamics of viral load in plasma and HIV DNA in lymphocytes during highly active antiretroviral therapy (HAART): High viral burden in macrophages after 1 year of treatment. J Chemother 2001;13:188-94.  Back to cited text no. 21      
22.Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989;169:59-72.  Back to cited text no. 22      
23.Paredes R, Munoz J, Diaz I, Domingo P, Gurgui M, Clotet B. Leishmaniasis in HIV infection. J Postgrad Med 2003;49:39-49.  Back to cited text no. 23  [PUBMED]  Medknow Journal  
24.Reiner SL, Wang ZE, Hatam F, Scott P, Locksley RM. TH1 and TH2 cell antigen receptors in experimental leishmaniasis. Science 1993;259:1457-60.  Back to cited text no. 24      
25.Carvalho EM, Barral A, Pedral-Sampaio D, Barral-Netto M, Badaro R, Rocha H, et al. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis 1992;165:535-40.  Back to cited text no. 25      
26.Sacks DL, Lal SL, Shrivastava SN, Blackwell J, Neva FA. An analysis of T cell responsiveness in Indian kala-azar. J Immunol 1987;138:908-13.  Back to cited text no. 26      
27.Carvalho EM, Badaro R, Reed SG, Jones TC, Johnson WD Jr. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 1985;76:2066-9.  Back to cited text no. 27      
28.Holaday BJ, Pompeu MM, Jeronimo S, Texeira MJ, Sousa AA, Vasconcelos AW, et al. Potential role for interleukin-10 in the immunosuppression associated with kala azar. J Clin Invest 1993;92:2626-32.  Back to cited text no. 28      
29.Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, El Hassan AM, et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993;92:324-9.  Back to cited text no. 29      
30.Reiner SL, Locksley RM. Cytokines in the differentiation of Th1/Th2 CD4+ subsets in leishmaniasis. J Cell Biochem 1993;53:323-8.  Back to cited text no. 30      
31.Da Cruz AM, Conceicao-Silva F, Bertho AL, Coutinho SG. Leishmania-reactive CD4+ and CD8+ T cells associated with cure of human cutaneous leishmaniasis. Infect Immun 1994;62:2614-8.  Back to cited text no. 31      
32.Akuffo HO, Britton SF. Contribution of non-Leishmania-specific immunity to resistance to Leishmania infection in humans. Clin Exp Immunol 1992;87:58-64.  Back to cited text no. 32      
33.Maasho K, Sanchez F, Schurr E, Hailu A, Akuffo H. Indications of the protective role of natural killer cells in human cutaneous leishmaniasis in an area of endemicity. Infect Immun 1998;66:2698-704.  Back to cited text no. 33      
34.Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 1993;14:335-8.  Back to cited text no. 34      
35.Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995;378:88-91.  Back to cited text no. 35      
36.Piscopo TV, Mallia AC. Leishmaniasis. Postgrad Med J 2006;82:649-57.  Back to cited text no. 36      
37.Roberts LJ, Handman E, Foote SJ. Science, medicine, and the future: Leishmaniasis. BMJ 2000;321:801-4.  Back to cited text no. 37      
38.Blackwell JM, Mohamed HS, Ibrahim ME. Genetics and visceral leishmaniasis in the Sudan: Seeking a link. Trends Parasitol 2004;20:268-74.  Back to cited text no. 38      
39.Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-45.  Back to cited text no. 39      
40.Liese J, Schleicher U, Bogdan C. The innate immune response against Leishmania parasites. Immunobiology 2008;213:377-87.  Back to cited text no. 40      
41.Sieling PA, Modlin RL. Activation of toll-like receptors by microbial lipoproteins. Scand J Infect Dis 2001;33:97-100.  Back to cited text no. 41      
42.Thoma-Uszynski S, Stenger S, Takeuchi O, Ochoa MT, Engele M, Sieling PA, et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001;291:1544-7.  Back to cited text no. 42      
43.Lai Y, Gallo RL. Toll-like receptors in skin infections and inflammatory diseases. Infect Disord Drug Targets 2008;8:144-55.  Back to cited text no. 43      
44.Curry JL, Qin JZ, Bonish B, Carrick R, Bacon P, Panella J, et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 2003;127:178-86.  Back to cited text no. 44      
45.Song PI, Park YM, Abraham T, Harten B, Zivony A, Neparidze N, et al. Human keratinocytes express functional CD14 and toll-like receptor 4. J Invest Dermatol 2002;119:424-32.  Back to cited text no. 45      
46.Martinez-Salazar B, Berzunza-Cruz M, Becker I. [Leishmania mexicana DNA activates murine macrophages and increases their TLR9 expression]. Gac Med Mex 2008;144:99-104.  Back to cited text no. 46      
47.Liese J, Schleicher U, Bogdan C. TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis. Eur J Immunol 2007;37:3424-34.  Back to cited text no. 47      
48.Maurer M, Dondji B, von Stebut E. What determines the success or failure of intracellular cutaneous parasites? Lessons learned from leishmaniasis. Med Microbiol Immunol 2009;198:137-46.  Back to cited text no. 48      
49.Antoniazi S, Price HP, Kropf P, Freudenberg MA, Galanos C, Smith DF, et al. Chemokine gene expression in toll-like receptor-competent and -deficient mice infected with Leishmania major. Infect Immun 2004;72:5168-74.  Back to cited text no. 49      
50.Muraille E, De Trez C, Brait M, De Baetselier P, Leo O, Carlier Y. Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response. J Immunol 2003;170:4237-41.  Back to cited text no. 50      
51.Kostka SL, Knop J, Konur A, Udey MC, von Stebut E. Distinct roles for IL-1 receptor type I signaling in early versus established Leishmania major infections. J Invest Dermatol 2006;126:1582-9.  Back to cited text no. 51      
52.Dominguez M, Moreno I, Aizpurua C, Torano A. Early mechanisms of Leishmania infection in human blood. Microbes Infect 2003;5:507-13.  Back to cited text no. 52      
53.Xu G, Liu D, Okwor I, Wang Y, Korner H, Kung SK, et al. LIGHT is critical for IL-12 production by dendritic cells, optimal CD4+ Th1 cell response, and resistance to Leishmania major. J Immunol 2007;179:6901-9.  Back to cited text no. 53      
54.Kirkpatrick CE, Farrell JP. Leishmaniasis in beige mice. Infect Immun 1982;38:1208-16.  Back to cited text no. 54      
55.Resnick M, Roguel N, Bercovier H, Enk C, Frankenburg S, Kedar E. Lysis of murine macrophages infected with intracellular pathogens by interleukin 2-activated killer (LAK) cells in vitro . Cell Immunol 1988;113:214-9.  Back to cited text no. 55      
56.Scharton TM, Scott P. Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 1993;178:567-77.  Back to cited text no. 56      
57.Brodskyn CI, Barral A, Boaventura V, Carvalho E, Barral-Netto M. Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal leishmaniasis. J Immunol 1997;159:4467-73.  Back to cited text no. 57      
58.Roder J, Duwe A. The beige mutation in the mouse selectively impairs natural killer cell function. Nature 1979;278:451-3.  Back to cited text no. 58      
59.Scharton-Kersten T, Scott P. The role of the innate immune response in Th1 cell development following Leishmania major infection. J Leukoc Biol 1995;57:515-22.  Back to cited text no. 59      
60.Wei XQ, Leung BP, Niedbala W, Piedrafita D, Feng GJ, Sweet M, et al. Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol 1999;163:2821-8.  Back to cited text no. 60      
61.Heinzel FP, Rerko RM, Hatam F, Locksley RM. IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. J Immunol 1993;150:3924-31.  Back to cited text no. 61      
62.Murray HW, Hariprashad J. Interleukin 12 is effective treatment for an established systemic intracellular infection: Experimental visceral leishmaniasis. J Exp Med 1995;181:387-91.  Back to cited text no. 62      
63.Vester B, Muller K, Solbach W, Laskay T. Early gene expression of NK cell-activating chemokines in mice resistant to Leishmania major. Infect Immun 1999;67:3155-9.  Back to cited text no. 63      
64.Laskay T, Diefenbach A, Rollinghoff M, Solbach W. Early parasite containment is decisive for resistance to Leishmania major infection. Eur J Immunol 1995;25:2220-7.  Back to cited text no. 64      
65.Gorak PM, Engwerda CR, Kaye PM. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol 1998;28:687-95.  Back to cited text no. 65      
66.Berberich C, Ramirez-Pineda JR, Hambrecht C, Alber G, Skeiky YA, Moll H. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 2003;170:3171-9.  Back to cited text no. 66      
67.Becker I, Salaiza N, Aguirre M, Delgado J, Carrillo-Carrasco N, Kobeh LG, et al. Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol 2003;130:65-74.  Back to cited text no. 67      
68.Nylen S, Maasho K, Soderstrom K, Ilg T, Akuffo H. Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clin Exp Immunol 2003;131:457-67.  Back to cited text no. 68      
69.Reed SG, Scott P. T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 1993;5:524-31.  Back to cited text no. 69      
70.Mansueto P, Vitale G, Di Lorenzo G, Rini GB, Mansueto S, Cillari E. Immunopathology of leishmaniasis: An update. Int J Immunopathol Pharmacol 2007;20:435-45.  Back to cited text no. 70      
71.Sundar S, Reed SG, Sharma S, Mehrotra A, Murray HW. Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg 1997;56:522-5.  Back to cited text no. 71      
72.Ruiz JH, Becker I. CD8 cytotoxic T cells in cutaneous leishmaniasis. Parasite Immunol 2007;29:671-8.  Back to cited text no. 72      
73.Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 2007;204:805-17.  Back to cited text no. 73      
74.Karp CL, Auwaerter PG. Coinfection with HIV and tropical infectious diseases. I. Protozoal pathogens. Clin Infect Dis 2007;45:1208-13.  Back to cited text no. 74      
75.Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al. Visceral leishmaniasis: What are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007;5:873-82.  Back to cited text no. 75      
76.Cruz I, Morales MA, Noguer I, Rodriguez A, Alvar J. Leishmania in discarded syringes from intravenous drug users. Lancet 2002;359:1124-5.  Back to cited text no. 76      
77.Wolday D, Akuffo H, Britton S, Hathaway A, Sander B. HIV-1 inhibits Leishmania-induced cell proliferation but not production of interleukin-6 and tumour necrosis factor alpha. Scand J Immunol 1994;39:380-6.  Back to cited text no. 77      
78.Moreno J, Canavate C, Chamizo C, Laguna F, Alvar J. HIV-Leishmania infantum co-infection: Humoral and cellular immune responses to the parasite after chemotherapy. Trans R Soc Trop Med Hyg 2000;94:328-32.  Back to cited text no. 78      
79.Bentwich Z. Concurrent infections that rise the HIV viral load. J HIV Ther 2003;8:72-5.  Back to cited text no. 79      
80.Bernier R, Turco SJ, Olivier M, Tremblay M. Activation of human immunodeficiency virus type 1 in monocytoid cells by the protozoan parasite Leishmania donovani. J Virol 1995;69:7282-5.  Back to cited text no. 80      
81.Garg R, Barat C, Ouellet M, Lodge R, Tremblay MJ. Leishmania infantum amastigotes enhance hiv-1 production in cocultures of human dendritic cells and cd4 t cells by inducing secretion of il-6 and tnf-alpha. PLoS Negl Trop Dis 2009;3:e441.  Back to cited text no. 81      
82.Olivier M, Badaro R, Medrano FJ, Moreno J. The pathogenesis of Leishmania/HIV co-infection: Cellular and immunological mechanisms. Ann Trop Med Parasitol 2003;97:79-98.  Back to cited text no. 82      
83.Oyaizu N, Chirmule N, Kalyanaraman VS, Hall WW, Pahwa R, Shuster M, et al. Human immunodeficiency virus type 1 envelope glycoprotein gp120 produces immune defects in CD4+ T lymphocytes by inhibiting interleukin 2 mRNA. Proc Natl Acad Sci U S A 1990;87:2379-83.  Back to cited text no. 83      
84.Gazzinelli RT, Bala S, Stevens R, Baseler M, Wahl L, Kovacs J, et al. HIV infection suppresses type 1 lymphokine and IL-12 responses to Toxoplasma gondii but fails to inhibit the synthesis of other parasite-induced monokines. J Immunol 1995;155:1565-74.  Back to cited text no. 84      
85.Murray HW. Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDS 1999;13:459-65.  Back to cited text no. 85      
86.Akuffo H, Maasho K, Blostedt M, Hojeberg B, Britton S, Bakhiet M. Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for interleukin-10 while those from localized leishmaniasis patients induce interferon-gamma. J Infect Dis 1997;175:737-41.  Back to cited text no. 86      
87.Chaudhary RG, Bilimoria FE, Katare SK. Diffuse cutaneous leishmaniasis: Co-infection with human immunodeficiency virus (HIV). Indian J Dermatol Venereol Leprol 2008;74:641-3.  Back to cited text no. 87  [PUBMED]  Medknow Journal  
88.Mehta V, Balachandran C, Rao R, Dil SK, Indusri L. Diffuse cutaneous leishmaniasis in HIV. Dermatol Online J 2009;15:9.  Back to cited text no. 88      
89.Egea VJ, Banos MR, Rodrigo Agudo JL, Galera PC, Torroba A, Molina MJ, et al. Duodenal leishmaniasis in a HIV patient. Rev Esp Enferm Dig 2009;101:60-2.  Back to cited text no. 89      
90.Alvar J, Canavate C, Gutierrez-Solar B, Jimenez M, Laguna F, Lopez-Velez R, et al. Leishmania and human immunodeficiency virus coinfection: The first 10 years. Clin Microbiol Rev 1997;10:298-319.  Back to cited text no. 90      
91.Hailu A, Berhe N. The performance of direct agglutination tests (DAT) in the diagnosis of visceral leishmaniasis among Ethiopian patients with HIV co-infection. Ann Trop Med Parasitol 2002;96:25-30.  Back to cited text no. 91      
92.Deniau M, Canavate C, Faraut-Gambarelli F, Marty P. The biological diagnosis of leishmaniasis in HIV-infected patients. Ann Trop Med Parasitol 2003;97:115-33.  Back to cited text no. 92      
93.Herrera E, Sanchez P, Bosch RJ. Disseminated cutaneous leishmaniasis in an HIV-infected patient. Int J STD AIDS 1995;6:125-6.  Back to cited text no. 93      
94.Niamba P, Goumbri-Lompo O, Traore A, Barro-Traore F, Soudre RT. Diffuse cutaneous leishmaniasis in an HIV-positive patient in western Africa. Australas J Dermatol 2007;48:32-4.  Back to cited text no. 94      
95.Pasquau F, Ena J, Sanchez R, Cuadrado JM, Amador C, Flores J, et al. Leishmaniasis as an opportunistic infection in HIV-infected patients: Determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region. Eur J Clin Microbiol Infect Dis 2005;24:411-8.  Back to cited text no. 95      
96.Pintado V, Lopez-Velez R. HIV-associated visceral leishmaniasis. Clin Microbiol Infect 2001;7:291-300.  Back to cited text no. 96      
97.Santos LO, Marinho FA, Altoe EF, Vitorio BS, Alves CR, Britto C, et al. HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis. PLoS One 2009;4:e4918.  Back to cited text no. 97      
98.Sindermann H, Engel KR, Fischer C, Bommer W. Oral miltefosine for leishmaniasis in immunocompromised patients: Compassionate use in 39 patients with HIV infection. Clin Infect Dis 2004;39:1520-3.  Back to cited text no. 98      
99.Davidson RN, Di Martino L, Gradoni L, Giacchino R, Russo R, Gaeta GB, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: A multi-centre trial. Q J Med 1994;87:75-81.  Back to cited text no. 99      
100.Laguna F, Lopez-Velez R, Pulido F, Salas A, Torre-Cisneros J, Torres E, et al. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 1999;13:1063-9.  Back to cited text no. 100      
101.Piscopo TV, Mallia AC. Leishmaniasis. Postgrad Med J 2007;83:649-57.  Back to cited text no. 101      
102.Marques N, Sa R, Coelho F, Oliveira J, Saraiva DC, Melico-Silvestre A. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients. Scand J Infect Dis 2008;40:523-6.  Back to cited text no. 102      
103.Troya J, Casquero A, Refoyo E, Fernandez-Guerrero ML, Gorgolas M. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. Scand J Infect Dis 2008;40:78-80.  Back to cited text no. 103      
104.Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006;43:357-64.  Back to cited text no. 104      
105.Collini P, Premchand N, Lockwood D, Greig J. Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: A case report and brief review of the literature. Ann Trop Med Parasitol 2009;103:455-9.  Back to cited text no. 105      
106.Goldsmith DR, Perry CM. Amphotericin B lipid complex: In visceral leishmaniasis. Drugs 2004;64:1905-11.  Back to cited text no. 106      
107.Kafetzis DA, Velissariou IM, Stabouli S, Mavrikou M, Delis D, Liapi G. Treatment of paediatric visceral leishmaniasis: Amphotericin B or pentavalent antimony compounds? Int J Antimicrob Agents 2005;25:26-30.  Back to cited text no. 107      
108.Lopez-Velez R, Perez-Molina JA, Guerrero A, Baquero F, Villarrubia J, Escribano L, et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg 1998;58:436-43.  Back to cited text no. 108      
109.Mira JA, Corzo JE, Rivero A, Macias J, De Leon FL, Torre-Cisneros J, et al. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 2004;70:298-301.  Back to cited text no. 109      
110.Fernandez Cotarelo MJ, Abellan MJ, Guerra Vales JM, Martinez SP, Rodrigo Gomez De La Barcena, Salto FE. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2003;37:973-7.  Back to cited text no. 110      
111.Lopez-Velez R. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Ann Trop Med Parasitol 2003;97:143-7.  Back to cited text no. 111      
112.Rosenthal E, Tempesta S, del Giudice P, Marty P, Desjeux P, Pradier C, et al. Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy. AIDS 2001;15:1184-5.  Back to cited text no. 112 la RR, Pineda JA, Delgado J, Macias J, Morillas F, Martin-Sanchez J, et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2001;32:633-5.  Back to cited text no. 113      

Correspondence Address:
Noah Craft
Department of Medicine, Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles; Department of Medicine, Divisions of Dermatology and Infectious Diseases, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0974-777X.68528

Rights and Permissions


  [Figure 1]

This article has been cited by
1 Epidemiological, clinical and hematological profiles of visceral leishmaniasis among patients visiting Tefera Hailu Memorial Hospital, Northeast Ethiopia: a 4 year retrospective study
Habtu Debash, Habtye Bisetegn, Marye Nigatie, Getu Abeje, Daniel Getacher Feleke
Scientific Reports. 2023; 13(1)
[Pubmed] | [DOI]
2 Synthesis of new 3-acetyl-1,3,4-oxadiazolines combined with pyrimidines as antileishmanial and antiviral agents
Saida Lachhab, Az-eddine El Mansouri, Ahmad Mehdi, Indira Dennemont, Johan Neyts, Dirk Jochmans, Graciela Andrei, Robert Snoeck, Yogesh S. Sanghvi, Mustapha Ait Ali, Philippe M. Loiseau, Hassan B. Lazrek
Molecular Diversity. 2022;
[Pubmed] | [DOI]
3 Bioinformatics Analysis to Designing a Multi-epitope-based Peptide Vaccine Combat Leishmania major
Arian Karimi Rouzbahani, Farnaz Kheirandish, Pejman Hashemzadeh
Iranian Journal of Medical Microbiology. 2022; 16(5): 430
[Pubmed] | [DOI]
4 Potential therapeutic targets shared between leishmaniasis and cancer
Sajad Rashidi, Celia Fernández-Rubio, Raúl Manzano-Román, Reza Mansouri, Reza Shafiei, Mohammad Ali-Hassanzadeh, Afshin Barazesh, Mohammadreza Karimazar, Gholamreza Hatam, Paul Nguewa
Parasitology. 2021; 148(6): 655
[Pubmed] | [DOI]
5 A Case–Control Study on the Association Between Intestinal Helminth Infections and Treatment Failure in Patients With Cutaneous Leishmaniasis
Dalila Y Martínez, Alejandro Llanos-Cuentas, Jean-Claude Dujardin, Katja Polman, Vanessa Adaui, Marleen Boelaert, Kristien Verdonck
Open Forum Infectious Diseases. 2020; 7(5): 883
[Pubmed] | [DOI]
6 Higher levels of TNF and IL-4 cytokines and low miR-182 expression in visceral leishmaniasis-HIV co-infected patients
Walter Lins Barbosa Júnior, Alda Maria Justo, Ana Maria Aguiar dos Santos, Virginia Maria Barros Lorena, Rodrigo Feliciano Carmo, Fábio Lopes Melo, Zulma Maria Medeiros, Luydson Richardson Silva Vasconcelos
Parasite Immunology. 2020; 42(4)
[Pubmed] | [DOI]
7 Fluralaner (Bravecto®) induces long-term mortality of Lutzomyia longipalpis after a blood meal in treated dogs
Tamyres Bernadete Dantas Queiroga, Henrique Rafael Pontes Ferreira, Wilo Victor dos Santos, Ana Beatriz Lourenço de Assis, Vicente Toscano de Araújo Neto, Antônia Cláudia Jácome da Câmara, João Ciro Fagundes Neto, Romeika Karla dos Reis, Manuela Sales Lima Nascimento, Renata Antonaci Gama, Paulo Marcos Matta Guedes
Parasites & Vectors. 2020; 13(1)
[Pubmed] | [DOI]
Nu Phuong Anh Ton, Thi Minh Chau Ngo, Chi Cao Le, Thi Bich Thao Do, Hung Viet Phan, Nu Thuy Duong Ha
Journal of Medicine and Pharmacy. 2019; : 106
[Pubmed] | [DOI]
9 Spectrum of clinicohematological profile and its correlation with average parasite density in visceral leishmaniasis
Vijay Kumar, Poojan Agarwal, Sadhna Marwah, A. S. Nigam, Awantika Tiwari
CytoJournal. 2018; 15: 19
[Pubmed] | [DOI]
10 Indian visceral leishmaniasis with extensive lymphadenopathy – An unusual presentation: A case report with literature review
Poojan Agarwal, Vijay Kumar, Manju Kaushal, Manju Kumari, Arvind Chaudhary
CytoJournal. 2017; 14: 9
[Pubmed] | [DOI]
11 Green Synthesis of Silver and Titanium Dioxide Nanoparticles Using Euphorbia prostrata Extract Shows Shift from Apoptosis to G 0 /G 1 Arrest followed by Necrotic Cell Death in Leishmania donovan
Abdul Abduz Zahir, Indira Singh Chauhan, Asokan Bagavan, Chinnaperumal Kamaraj, Gandhi Elango, Jai Shankar, Nidhi Arjaria, Selvaraj Mohana Roopan, Abdul Abdul Rahuman, Neeloo Singh
Antimicrobial Agents and Chemotherapy. 2015; 59(8): 4782
[Pubmed] | [DOI]
12 Immunity to visceral leishmaniasis: implications for immunotherapy
Forough Khadem,Jude E Uzonna
Future Microbiology. 2014; 9(7): 901
[Pubmed] | [DOI]
13 Post-Kala-Azar Dermal Leishmaniasis: A Paradigm of Paradoxical Immune Reconstitution Syndrome in Non-HIV/AIDS Patients
Eltahir Awad Gasim Khalil,Selma Abdelmoneim Khidir,Ahmed Mudawi Musa,Brema Younis Musa,Mona Elfaki Eltahir Elfaki,Abdelgadir Mohamed Yousif Elkadaru,Edward Zijlstra,Ahmed Mohamed El-Hassan
Journal of Tropical Medicine. 2013; 2013: 1
[Pubmed] | [DOI]
14 Inhibitory effect of citrinin on lipopolisaccharide-induced nitric oxide production by mouse macrophage cells
Kei-ichi Sugiyama,Rino Yamazaki,Mawo Kinoshita,Yoichi Kamata,Fumito Tani,Yuji Minai,Yoshiko Sugita-Konishi
Mycotoxin Research. 2013; 29(4): 229
[Pubmed] | [DOI]
15 Visceral leishmaniasis: host–parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host
Laura Saporito,Giovanni M. Giammanco,Simona De Grazia,Claudia Colomba
International Journal of Infectious Diseases. 2013; 17(8): e572
[Pubmed] | [DOI]
16 Epidemiology of human immunodeficiency virus-visceral leishmaniasis-co-infection
Patrícia Rodrigues Naufal Spir,Lourdes Aparecida Zampieri DæAndrea,Elivelton Silva Fonseca,Luiz Euribel Prestes-Carneiro
Journal of Microbiology, Immunology and Infection. 2013;
[Pubmed] | [DOI]
17 Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: results of a large cross-sectional study
Omer Bébé Ngouateu,Pierre Kollo,Christophe Ravel,Jacques Dereure,Pierre Kamtchouing,Albert Same-Ekobo,Esther von Stebut,Marcus Maurer,Blaise Dondji
Transactions of the Royal Society of Tropical Medicine and Hygiene. 2012; 106(3): 137
[Pubmed] | [DOI]
18 Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection
S.A. Campbell,J. Alawa,B. Doro,F.L. Henriquez,C.W. Roberts,A. Nok,C.B.I. Alawa,M. Alsaadi,A.B. Mullen,K.C. Carter
Vaccine. 2012; 30(7): 1357
[Pubmed] | [DOI]
19 Leishmaniasis visceral insospechada infiltrando un carcinoma epidermoide
M. Armengot-Carbó,R. Carmena-Ramón,B. Rodrigo-Nicolás,J. Ferrando-Marco
Actas Dermo-Sifiliográficas. 2012; 103(4): 321
[Pubmed] | [DOI]
20 Unsuspected Visceral Leishmaniasis Infiltrating a Squamous Cell Carcinoma
M. Armengot-Carbó,R. Carmena-Ramón,B. Rodrigo-Nicolás,J. Ferrando-Marco
Actas Dermo-Sifiliográficas (English Edition). 2012; 103(4): 321
[Pubmed] | [DOI]
21 Leishmaniasis with oral mucosa involvement
Ana C. A. Pellicioli,Marco A. T. Martins,Manoel Sant’ana Filho,Pantelis V. Rados,Manoela D. Martins
Gerodontology. 2012; 29(2): e1168
[Pubmed] | [DOI]
22 Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems
Delaram Doroud,Sima Rafati
Expert Review of Vaccines. 2012; 11(1): 69
[Pubmed] | [DOI]
23 Clinical pleiomorphism in human leishmaniases, with special mention of asymptomatic infection
A. L. Bañuls,P. Bastien,C. Pomares,J. Arevalo,R. Fisa,M. Hide
Clinical Microbiology and Infection. 2011; 17(10): 1451
[Pubmed] | [DOI]
24 Disseminated rhodococcus equi infection in HIV infection despite highly active antiretroviral therapy
Francesca Ferretti,Antonio Boschini,Cristiana Iabichino,Simonetta Gerevini,Paola De Nardi,Monica Guffanti,Giuseppe Balconi,Adriano Lazzarin,Paola Cinque
BMC Infectious Diseases. 2011; 11(1): 343
[Pubmed] | [DOI]
25 Innate Immunity and Leishmania Vaccination Strategies
Ron Birnbaum,Noah Craft
Dermatologic Clinics. 2011; 29(1): 89
[Pubmed] | [DOI]
26 Activity and turnover of eosinophil and neutrophil granulocytes are altered in visceral leishmaniasis
Amir I. Elshafie,Erik Åhlin,Lena Douhan Håkansson,Gehad Elghazali,Sayda Hassan El Safi,Johan Rönnelid,Per Venge
International Journal for Parasitology. 2011; 41(3-4): 463
[Pubmed] | [DOI]
27 PLGA nanoparticles loaded with the antileishmanial saponin ß-aescin: Factor influence study and in vitro efficacy evaluation
H. Van de Ven,M. Vermeersch,A. Matheeussen,J. Vandervoort,W. Weyenberg,S. Apers,P. Cos,L. Maes,A. Ludwig
International Journal of Pharmaceutics. 2011; 420(1): 122
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  

    HIV Immunology
    Article Figures

 Article Access Statistics
    PDF Downloaded363    
    Comments [Add]    
    Cited by others 27    

Recommend this journal

Sitemap | What's New | Feedback | Copyright and Disclaimer | Privacy Notice | Contact Us
© 2008 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow
Online since 10th December, 2008